106 related articles for article (PubMed ID: 8547132)
41. The lymphoid cell surface receptor NTB-A: a novel monoclonal antibody target for leukaemia and lymphoma therapeutics.
Korver W; Singh S; Liu S; Zhao X; Yonkovich S; Sweeney A; Anton K; Lomas WE; Greenwood R; Smith A; Tran DH; Shinkawa P; Jimenez M; Yeung P; Aguilar G; Palencia S; Vatta P; Mueller M; Zhan X; Newton EM; Liu Y; Zhao J; Emtage P; Levy MD; Hsi ED; Funk WD; Abo A
Br J Haematol; 2007 May; 137(4):307-18. PubMed ID: 17456053
[TBL] [Abstract][Full Text] [Related]
42. The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth.
Murakami-Mori K; Taga T; Kishimoto T; Nakamura S
Int Immunol; 1996 Apr; 8(4):595-602. PubMed ID: 8722639
[TBL] [Abstract][Full Text] [Related]
43. Myelomonocytic antigens are rarely expressed on B-lymphocytic leukemia cells.
Polliack A; Rabinowitz R; Leizerowitz R; Keren-Zur Y; Schlesinger M
Leuk Lymphoma; 1993 Jan; 9(1-2):125-31. PubMed ID: 8477192
[TBL] [Abstract][Full Text] [Related]
44. Expression of Ki-67 nuclear antigen in B and T cell lymphoproliferative disorders.
de Melo N; Matutes E; Cordone I; Morilla R; Catovksy D
J Clin Pathol; 1992 Aug; 45(8):660-3. PubMed ID: 1401173
[TBL] [Abstract][Full Text] [Related]
45. CD79a detected by ZL7.4 separates chronic lymphocytic leukemia from mantle cell lymphoma in the leukemic phase.
Bell PB; Rooney N; Bosanquet AG
Cytometry; 1999 Jun; 38(3):102-5. PubMed ID: 10397328
[TBL] [Abstract][Full Text] [Related]
46. Development of a monoclonal antibody-based enzyme-linked immunoabsorbent assay for the binding of gp130 to the IL-6/IL-6R complex and its competitive inhibition.
Scheller J; Kovaleva M; Rabe B; Eichler J; Kallen KJ; Rose-John S
J Immunol Methods; 2004 Aug; 291(1-2):93-100. PubMed ID: 15345308
[TBL] [Abstract][Full Text] [Related]
47. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
48. CD45 expression in low-grade B-cell non-Hodgkin's lymphomas.
Carulli G; Cannizzo E; Zucca A; Buda G; Orciuolo E; Marini A; Petrini M
Leuk Res; 2008 Feb; 32(2):263-7. PubMed ID: 17692374
[TBL] [Abstract][Full Text] [Related]
49. Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia.
Rezvany MR; Jeddi-Tehrani M; Rabbani H; Lewin N; Avila-Cariño J; Osterborg A; Wigzell H; Mellstedt H
Br J Haematol; 2000 Nov; 111(2):608-17. PubMed ID: 11122109
[TBL] [Abstract][Full Text] [Related]
50. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies.
Hara T; Kojima A; Fukuda H; Masaoka T; Fukumori Y; Matsumoto M; Seya T
Br J Haematol; 1992 Oct; 82(2):368-73. PubMed ID: 1384649
[TBL] [Abstract][Full Text] [Related]
51. Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Pabst T; Peters UR; Tinguely M; Schwaller J; Tschan M; Aebi S; Vonlanthen S; Borisch B; Betticher DC; Zimmermann A; Tobler A; Fey MF
Leuk Lymphoma; 2000 May; 37(5-6):639-48. PubMed ID: 11042528
[TBL] [Abstract][Full Text] [Related]
52. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.
Matolcsy A; Chadburn A; Knowles DM
Am J Pathol; 1995 Jul; 147(1):207-16. PubMed ID: 7541611
[TBL] [Abstract][Full Text] [Related]
53. Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells.
Jiang XP; Yang DC; Elliott RL; Head JF
Anticancer Res; 2011 Sep; 31(9):2899-906. PubMed ID: 21868536
[TBL] [Abstract][Full Text] [Related]
54. gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells.
Sui X; Tsuji K; Tanaka R; Tajima S; Muraoka K; Ebihara Y; Ikebuchi K; Yasukawa K; Taga T; Kishimoto T
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2859-63. PubMed ID: 7535932
[TBL] [Abstract][Full Text] [Related]
55. Interleukin-6 and its soluble receptor regulate the expression of insulin-like growth factor binding protein-5 in osteoblast cultures.
Franchimont N; Durant D; Canalis E
Endocrinology; 1997 Aug; 138(8):3380-6. PubMed ID: 9231791
[TBL] [Abstract][Full Text] [Related]
56. S-phase induction by interleukin-6 followed by chemotherapy in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Brown PD; Diamant M; Jensen PO; Geisler CH; Mortensen BT; Nissen NI
Leuk Lymphoma; 1999 Jul; 34(3-4):325-33. PubMed ID: 10439369
[TBL] [Abstract][Full Text] [Related]
57. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6.
Mitsuyama K; Toyonaga A; Sasaki E; Ishida O; Ikeda H; Tsuruta O; Harada K; Tateishi H; Nishiyama T; Tanikawa K
Gut; 1995 Jan; 36(1):45-9. PubMed ID: 7890234
[TBL] [Abstract][Full Text] [Related]
58. CD5-positive B-cell malignancies frequently express cross-reactive idiotypes associated with IgM autoantibodies.
Kipps TJ; Robbins BA; Tefferi A; Meisenholder G; Banks PM; Carson DA
Am J Pathol; 1990 Apr; 136(4):809-16. PubMed ID: 1691593
[TBL] [Abstract][Full Text] [Related]
59. Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias.
Ohtani K; Ninomiya H; Hasegawa Y; Kobayashi T; Kojima H; Nagasawa T; Abe T
Br J Haematol; 1995 Sep; 91(1):116-20. PubMed ID: 7577617
[TBL] [Abstract][Full Text] [Related]
60. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group.
Pulkki K; Pelliniemi TT; Rajamäki A; Tienhaara A; Laakso M; Lahtinen R
Br J Haematol; 1996 Feb; 92(2):370-4. PubMed ID: 8603002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
